Stichting Health Action International

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 20 Apr 2016
How to read and use this data card.
Download this datacard

Overview

WARNING: As this organisation lists one or more EP accredited lobbyists, it may not be probable that its lobbying costs are lower than €10,000.

Lobbying Costs

9,999€

Financial year: Jan 2014 - Dec 2014

Lobbyists (Full time equivalent)

5 Fte (6)

Lobbyists with EP accreditation

3

High-level Commission meetings

5

Lobbying Costs over the years

  • Info

    Stichting Health Action International   (HAI)

    EU Transparency Register

    44361352681-84 First registered on 30 Nov 2009

    Goals / Remit

    The mission of HAI is to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy. All regional offices share the same vision and common philosophies and work with their partners to achieve the targets that are set out in annual workplans; these targets are based on the three pillars of access to essential medicines; rational use of medicines; and democratisation of medicines policy. Though these targets have a common, global, aim, they are tailored to suit the prevailing local conditions for each region. Collaboration between the various groups within the 4 regions with the Global office leads to strong partnerships and a high level of commitment.
    The work of HAI is based on three pillars: access to essential medicines; rational use of medicines; and democratisation of medicines policy. It encompasses patients and consumers in more than 70 countries worldwide; in Europe HAI represents the interests of approx. 120 concerned groups and individuals in 22 European countries (18 from the European Union).
    A significant part of HAI Europe work lies in the field of advocacy and guiding medicine policy formulated at the European Parliament on behalf of consumers and patients in the European Union. This work is carried out in collaboration with various stakeholders, including public health orientated NGOs and Members of the European Parliament and is informed by high-level policy research and analysis. Campaigns carried out ensure that public awareness is raised to press decision-makers in governments and European institutions to introduce policies and enforce best practices in the field of improving public health.

    Main EU files targeted

    EU proposal for a Trade Secrets Directive, EU Clinical Trial Regulation, Trans-atlantic Trade and Investment Partnership Agreement, EMA policies (Access to documents, adaptive licensing, scientific advice and COI policy), EMA discharge, the updated EU trade and investment strategy for jobs and growth, the Innovative Medicines Initiative, EU pharmacovigilance Regulation, EU Access to Documents Regulation, Horizon 2020, EU IP enforcement strategy vis-à-vis third countries, proposal for new rules on the EU Transparency Register.

    Address

    Head Office
    Overtoom, 60/II
    Amsterdam 1054HK
    NETHERLANDS
  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    100%3
    75%2
    50%1

    Lobbyists (Full time equivalent)

    5

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    3 accreditations were / are live (in bold) for the selected state of 20 Apr 2016

    Name Start date End Date
    Ms Hannah VAN KOLFSCHOOTEN 14 Dec 2022 14 Dec 2023
    Ms Janneke VAN OIRSCHOT 09 Dec 2022 09 Dec 2023
    Mr Jaume VIDAL 04 Nov 2022 04 Nov 2023
    Ms Ellie WHITE 27 Oct 2021 11 Feb 2022
    Mr Jaume VIDAL 27 Oct 2021 27 Oct 2022
    Mr Jaume VIDAL 19 Sep 2019 19 Sep 2020
    Ms Ellie WHITE 14 Sep 2019 12 Sep 2020
    Ms Ancel·la Santos Quintano 13 Oct 2018 25 Apr 2019
    Mr Jaume VIDAL 13 Oct 2018 19 Sep 2019
    Ms Ancel·la Santos Quintano 14 Oct 2017 13 Oct 2018
    Mr Jaume VIDAL 20 Jul 2017 07 Jul 2018
    Ms Tessel Mellema 07 Sep 2016 21 Jul 2017
    Ms Ancel·la Santos Quintano 07 Sep 2016 07 Sep 2017
    Ms Tessel Mellema 27 Aug 2015 26 Aug 2016
    Ms Ancel·la Santos Quintano 27 Aug 2015 26 Aug 2016
    Ms Aliénor Devalière 27 Aug 2015 23 Jun 2016
    Ms Ancel·la Santos Quintano 01 May 2014 05 Jun 2015
    Ms Aliénor Devalière 07 Jun 2014 05 Jun 2015
    Mrs Aliénor Devalière 07 Jun 2014 27 Jan 2015
    Ms Tessel Mellema 01 May 2014 05 Jun 2015
    Mrs Ancel·la Santos Quintano 01 May 2014 27 Jan 2015
    Ms Tessel Mellema 25 Jun 2013 01 May 2014
    Mrs Ancel·la Santos Quintano 30 May 2013 01 May 2014
    Ms Katrina Perehudoff 22 Sep 2012 17 Jun 2013
    Ms Tessel Mellema 20 Sep 2012 25 Jun 2013

    Complementary Information

    On behalf of HAI Europe, the persons listed below have had, during the reporting period (2013), four or more contacts with members or officials of the EU institutions, or they have spent 20 percent or more of their working time on behalf of HAI Europe carrying out such activities.
    1. Tessel Mellema
    2. Ancel·la Santos Quintano
    3. Tim Reed
    4. Aliénor Devalière

    Person in charge of EU relations

    Ms Ancel·la Santos Quintano (Policy Advisor)

    Person with legal responsibility

    Mr Tim Reed (Executive Director HAI)

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    HAI Europe is one of the 4 HAI regional coordination offices; it works in close collaboration with the HAI regional office for Asia & the Pacific (based in Penang, Malaysia), for Africa (based in Nairobi, Kenya) and for Latin America (based in Lima, Peru). The entire HAI network is coordinated from the HAI Global office located in Amsterdam, the Netherlands.

    HAI Europe is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins, Prescrire, the Trans-Atlantic Consumer Dialogue, the Medicines in Europe Forum and the Patients and Consumers Working Party (PCWP)and Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency. HAI Europe is a signatory to the Alliance for Lobby Transparency and Ethics Regulation in the EU (ALTER-EU). All these organisations have deep-seated knowledge of European public health policy, besides having access to international experts on a variety of health issues (notably pharmacovigilance). In addition HAI Europe enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required.

    HAI Europe collaborates with WHO on certain projects and is eligible to work with the European Medicines Agency.

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2014 - Dec 2014

    Lobbying costs for closed financial year

    9,999€

    EU grant income for closed financial year

    218,000 € (Source: CHAFEA)

    Other financial info

    The above estimated costs in representing HAI interests to European Institutions in 2013 was €145.000

    Grants received in 2013:
    Executive Agency for Health & Consumers : 218.000 euro
    Open Society Foundation : €70.965
    Own contribution: €93.188
    Contributions from members: €6.210
    Reference:http://haieurope.org/wp-content/uploads/2014/04/HAI-Financial-Statements-2013.pdf

    As part of the HAI network, HAI Europe is subject to rigorous and robust monitoring & evaluation protocols, evolved in partnership with the Dutch government. In addition, a dedicated M&E protocol for each of the strategic objectives in the annual work programme has been constructed to provide a transparent and valid assessment of each project; this is reflected in the Annual and Financial reports listed on the HAI website each year.

    HAI Europe maintains a strict policy to avoid conflicts of interest: no funds can be taken from the pharmaceutical industry. In addition, any financial relationship, or other beneficial interests, that could impact on working with HAI must be declared on a ‘Competing Interests form’ which is applicable to all members each year.

  • EU Structures

    Groups (European Commission)

    None

    ACC

    None

    Groups (European Parliament)

    None

    Communication activities

    None

    Other activities

    HAI Europe activities in 2013 were related to the following EU initiatives:
    Clinical Trials Regulation
    Transparency Directive
    EU Access to Documents Regulation
    EU Customs Regulation
    EU Thailand Free Trade Agreement
    EU US Free Trade Agreement
    EU-Mercosur Free Trade Agreement
    EU-India Free Trade Agreement
    Anti-Counterfeiting Trade Agreement
    European Research & Innovation Framework, Horizon 2020
    Staff regulations
    EMA policies on: the handling of potential conflicts of interest; ethical and GCP aspects of clinical trails in third countries; identification of commercially confidential information

  • Meetings

    Meetings

    5 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard